A plain language summary of the PALOMA-2 and PALOMA-3 studies: the effects of adding palbociclib to endocrine therapy to treat advanced breast cancer
This Plain Language Summary of Publication article from Future Oncology reports the results of two studies called PALOMA-2 and PALOMA-3. Both studies included women with a type of breast cancer called HR+/HER2− advanced breast cancer. The studies particularly focused on the effects of adding a medication called palbociclib (brand name, Ibrance®) to a hormone therapy.
Visit the Future Medicine site using the link to read the full article.
There is also an accompanying video.
This summary is based on two original articles that were both published in the The New England Journal of Medicine.
Visit the New England Journal of Medicine site using the link to read the article.
Visit the New England Journal of Medicine site using the link to read the article.